CUSIP 04272N102 · who reports it, how much, and how much it matters to them
20 of the 720 hedge fund managers we track reported shares of ArriVent BioPharma, Inc. (Nasdaq: AVBP) on Form 13F for 30 June 2026. Between them they reported USD 525m. The largest position belongs to Suvretta Capital Management, at USD 157m. The manager with the most riding on it is Octagon Capital Advisors, where it is 6.2% of the reported book.
Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated
Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.
A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.
Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.
The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Suvretta Capital Management4 funds on PPLI.com | USD 157m | 2.9% |
| 2 | Orbimed Advisors1 fund on PPLI.com | USD 105m | 1.9% |
| 3 | Octagon Capital Advisors1 fund on PPLI.com | USD 68m | 6.2% |
| 4 | Sofinnova Investments1 fund on PPLI.com | USD 59m | 3.0% |
| 5 | Logos Global Management1 fund on PPLI.com | USD 35m | 1.5% |
| 6 | D. E. Shaw & Co.15 funds on PPLI.com | USD 30m | 0.0% |
| 7 | POINT72 Asset Management17 funds on PPLI.com | USD 20m | 0.0% |
| 8 | Millennium Management6 funds on PPLI.com | USD 15m | 0.0% |
| 9 | Balyasny Asset Management25 funds on PPLI.com | USD 14m | 0.0% |
| 10 | Acuta Capital Partners2 funds on PPLI.com | USD 7.6m | 5.3% |
| 11 | Citadel Advisors32 funds on PPLI.com | USD 5.4m | 0.0% |
| 12 | Burkehill Global Management5 funds on PPLI.com | USD 3.5m | 0.1% |
| 13 | Two Sigma Investments35 funds on PPLI.com | USD 2m | 0.0% |
| 14 | Tudor Investment Corporation10 funds on PPLI.com | USD 809,000 | 0.0% |
| 15 | Engineers Gate Manager1 fund on PPLI.com | USD 773,000 | 0.0% |
| 16 | Squarepoint Ops7 funds on PPLI.com | USD 609,000 | 0.0% |
| 17 | Persistent Asset Partners10 funds on PPLI.com | USD 547,000 | 0.2% |
| 18 | Jain Global1 fund on PPLI.com | USD 399,000 | 0.0% |
| 19 | Aquatic Capital Management3 funds on PPLI.com | USD 368,000 | 0.0% |
| 20 | Brevan Howard Capital Management39 funds on PPLI.com | USD 307,000 | 0.0% |
A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Octagon Capital Advisors | USD 68m | 6.2% |
| 2 | Acuta Capital Partners | USD 7.6m | 5.3% |
| 3 | Sofinnova Investments | USD 59m | 3.0% |
| 4 | Suvretta Capital Management | USD 157m | 2.9% |
| 5 | Orbimed Advisors | USD 105m | 1.9% |
| 6 | Logos Global Management | USD 35m | 1.5% |
| 7 | Persistent Asset Partners | USD 547,000 | 0.2% |
| 8 | Burkehill Global Management | USD 3.5m | 0.1% |
| 9 | POINT72 Asset Management | USD 20m | 0.0% |
| 10 | Balyasny Asset Management | USD 14m | 0.0% |
ArriVent BioPharma, Inc. trades under the symbol AVBP on the Nasdaq. Its CUSIP, the code used on Form 13F, is 04272N102.
20 of the 720 hedge fund managers PPLI.com tracks reported ArriVent BioPharma, Inc. shares on Form 13F for 30 June 2026. The largest reported positions were held by Suvretta Capital Management (USD 157m), Orbimed Advisors (USD 105m), Octagon Capital Advisors (USD 68m), Sofinnova Investments (USD 59m) and Logos Global Management (USD 35m).
20 managers in our coverage reported it, and between them they run 216 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.
Octagon Capital Advisors, where the position was 6.2% of the reported 13F book at 30 June 2026.
No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.
Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with ArriVent BioPharma, Inc. or with the managers listed.
Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.
Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.